Literature DB >> 23857603

The translocation t(4;14) can be present only in minor subclones in multiple myeloma.

Benjamin Hébraud1, Denis Caillot, Jill Corre, Gérald Marit, Cyrille Hulin, Xavier Leleu, Laurence Lodé, Marc Wetterwald, Mamoun Dib, Philippe Rodon, Laurent Voillat, Bruno Royer, Eric Voog, Olivier Fitoussi, Anne-Marie Stoppa, Laurent Garderet, Brigitte Kolb, Michel Maigre, Nadine Boullanger, Olivier Allangba, Lionel Karlin, Nicolas Daguindau, Laurence Legros, Claudine Sohn, Marie-Véronique Joubert, Pascal Lenain, Thierry Facon, Michel Attal, Philippe Moreau, Hervé Avet-Loiseau.   

Abstract

PURPOSE: Although the translocation t(4;14) is supposed to be a primary event in multiple myeloma, we have been surprised to observe that in large relapse series of patients, the t(4;14) can be observed only in subpopulations of plasma cells, in contrast to what is seen at diagnosis. This observation raised the question of possible subclones harboring the translocation that would be observable only at the time of relapse. EXPERIMENTAL
DESIGN: To address this issue, we analyzed by FISH a cohort of 306 patients for whom we had at least two samples obtained at different disease phases.
RESULTS: We observed a "gain" of the t(4;14) in 14 patients, and conversely, a "loss" of the translocation in 11 patients. Two hypotheses were raised: either an acquisition of the translocation during evolution or the existence of small t(4;14)-positive subclones at the time of diagnosis. To address this question, we had the opportunity to analyze two patients at the time of diagnosis by RT-PCR (reverse transcription-polymerase chain reaction) to look for the chimeric Eμ-MMSET transcript, and one patient positive at diagnosis, but negative at relapse. The samples were positive, supporting the second hypothesis. Furthermore, the IGH sequences of two patients who "lose" the t(4;14) were identical at diagnosis and relapse, confirming the existence of a common ancestral clone.
CONCLUSION: Thus, the conclusion of this study is that the t(4;14) is not a primary event in multiple myeloma and that it can be present in silent subclones at diagnosis, but also at relapse. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23857603      PMCID: PMC4863228          DOI: 10.1158/1078-0432.CCR-12-3866

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

Review 2.  Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.

Authors:  Avet-Loiseau Hervé; Magrangeas Florence; Moreau Philippe; Attal Michel; Facon Thierry; Anderson Kenneth; Harousseau Jean-Luc; Munshi Nikhil; Minvielle Stéphane
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Authors:  Annemiek Broyl; Dirk Hose; Henk Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; H Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

4.  Minor clone provides a reservoir for relapse in multiple myeloma.

Authors:  F Magrangeas; H Avet-Loiseau; W Gouraud; L Lodé; O Decaux; P Godmer; L Garderet; L Voillat; T Facon; A M Stoppa; G Marit; C Hulin; P Casassus; M Tiab; E Voog; E Randriamalala; K C Anderson; P Moreau; N C Munshi; S Minvielle
Journal:  Leukemia       Date:  2012-08-09       Impact factor: 11.528

5.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

6.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

7.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 8.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

Review 9.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

Review 10.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

View more
  10 in total

Review 1.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 2.  Genetics of multiple myeloma: another heterogeneity level?

Authors:  Jill Corre; Nikhil Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

3.  The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Authors:  Simon Walz; Juliane S Stickel; Daniel Johannes Kowalewski; Heiko Schuster; Katja Weisel; Linus Backert; Stefan Kahn; Annika Nelde; Tatjana Stroh; Martin Handel; Oliver Kohlbacher; Lothar Kanz; Helmut Rainer Salih; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Blood       Date:  2015-07-02       Impact factor: 22.113

4.  A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.

Authors:  Stefania Oliva; Lorenzo De Paoli; Marina Ruggeri; Simona Caltagirone; Rossella Troia; Daniela Oddolo; Mattia D'Agostino; Milena Gilestro; Roberto Mina; Elona Saraci; Gloria Margiotta Casaluci; Elisa Genuardi; Sara Bringhen; Mario Boccadoro; Paola Omedé
Journal:  Ann Hematol       Date:  2021-01-03       Impact factor: 3.673

Review 5.  Molecular pathogenesis of multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Clin Oncol       Date:  2015-05-08       Impact factor: 3.402

6.  Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Authors:  Maximilian Merz; Anna Jauch; Thomas Hielscher; Elias K Mai; Anja Seckinger; Dirk Hose; Uta Bertsch; Kai Neben; Marc S Raab; Hans Salwender; Igor W Blau; Hans-Walter Lindemann; Ingo Schmidt-Wolf; Christof Scheid; Mathias Haenel; Katja Weisel; Hartmut Goldschmidt; Jens Hillengass
Journal:  Haematologica       Date:  2017-05-11       Impact factor: 9.941

Review 7.  The Evolution of Prognostic Factors in Multiple Myeloma.

Authors:  Amr Hanbali; Mona Hassanein; Walid Rasheed; Mahmoud Aljurf; Fahad Alsharif
Journal:  Adv Hematol       Date:  2017-02-21

8.  The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Authors:  Gordon Cook; Kara-Louise Royle; Sheila O'Connor; David A Cairns; A John Ashcroft; Cathy D Williams; Anna Hockaday; Jamie D Cavenagh; John A Snowden; Debo Ademokun; Eleni Tholouli; Vivienne E Andrews; Matthew Jenner; Christopher Parrish; Kwee Yong; Jim Cavet; Hannah Hunter; Jenny M Bird; Guy Pratt; Mark T Drayson; Julia M Brown; Treen C M Morris
Journal:  Br J Haematol       Date:  2019-02-06       Impact factor: 6.998

9.  Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; April N Meyer; Malcolm Casale; Matthew Hallowell; William R Wilcox; Daniel J Donoghue; Leslie Michels Thompson
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  Expressed fusion gene landscape and its impact in multiple myeloma.

Authors:  A Cleynen; R Szalat; M Kemal Samur; S Robiou du Pont; L Buisson; E Boyle; M L Chretien; K Anderson; S Minvielle; P Moreau; M Attal; G Parmigiani; J Corre; N Munshi; H Avet-Loiseau
Journal:  Nat Commun       Date:  2017-12-01       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.